Case Reports

WOMAN WITH AIDS AND STATUS EPILEPTICUS
Bonnie Callahan, MD
Case Presentation
A 42 year-old female with a medical history of HIV presented to
the Emergency Department with nausea and vomiting for the past
five days. Six days prior to presentation, she had one week of
symptoms of progressive dyspnea and non-productive cough which
were evaluated by her primary care physician. At that time, blood
work revealed a CD 4 count of 150 cells/mm3 and a chest x-ray
was suggestive of pneumonia. She was given a prescription of
trimethoprim-sulfamethoxazole (TMP/SMX) and guaifenesin
with codeine. Within twenty-four hours of starting the prescribed
medications, she developed nausea and vomiting, and she stopped
taking both medications three days prior to presentation. Although
her cough and shortness-of-breath were much improved, her
nausea and vomiting had not improved with discontinuation of
the TMP/SMX and guaifenesin with codeine. She reported she
was unable to tolerate any solid foods and was only tolerating small
amounts of liquids. She also noted some associated epigastric
“crampiness.” Review of systems was notable for a new headache
that started the morning of presentation to the hospital. The
headache was bilateral, frontal, and “achy, non-throbbing.” She
had no associated photophobia, vision change, or neck-stiffness.
She reported no fever, chills, chest pain, hemoptysis, diarrhea, or
constipation. She had no other complaints.
On review of the patient’s past medical history, she was noted to
have type 2 diabetes, hypertension, “mild” asthma (never
requiring hospitalization or intubation) and HIV/AIDS with a
recent CD4 count of 150 cells/mm3. Her surgical history
included a TAH-BSO and breast biopsy. She was allergic to
penicillin, which caused anaphylaxis. Her medications included
glipizide, amlodipine, losartan, hydrochlorothiazide, and
albuterol. Social history was negative for tobacco, alcohol, or
substance abuse. The patient worked in an office setting and lived
at home with her daughter. She reported no recent sick contacts
and no recent travel. Her family history was significant for type 2
diabetes in her mother, who died from a stroke at age sixty, and
breast cancer in her sister, who died from a stroke in her fifties.
In the ED, the patient was afebrile and her vital signs included a
heart rate of 92 beats per minute, respiratory rate of 16 breaths
per minute, blood pressure of 128/94 mmHg, and an oxygen
saturation of 98% on room air. She was alert and oriented and in
no acute distress. Physical exam revealed oral thrush and scattered
expiratory wheezes in bilateral lungs with decreased breath sounds
at bilateral bases. Her abdomen was diffusely tender, with
normoactive bowel sounds throughout and no rebound or
guarding. No masses or organomegaly were appreciated. The
physical exam was otherwise unremarkable.
The initial evaluation included a chest x-ray which showed “hilar
lymphadenopathy with upper lobe interstitial lung disease” which
was thought to be secondary to infectious etiology. Her urinalysis
was negative for infection, and a complete blood count showed a
normal white blood cell count, a normal platelet count, and mild
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anemia with hemoglobin of 12 g/dL. She had an elevated lactate
dehydrogenase of 287 IU/L. Her blood chemistries were normal,
with the exception of a creatinine of 2.0 mg/dL, with a known
baseline of 0.8 mg/dL one year earlier. Blood and sputum cultures
were collected. The patient was diagnosed with communityacquired pneumonia and was started on moxifloxacin in the ED.
She was also started on intravenous TMP/SMX for possible PCP
and fluconazole for her oral thrush. She was admitted to the
hospital and started on intravenous fluid resuscitation.
The first night of the patient’s hospital stay was uneventful. The
following morning she was noted to have acute mental status
change. She appeared awake, but would not answer questions or
follow commands. She had a low grade temperature of 100ºF, was
tachycardic at 110 beats per minute, with a blood pressure of
132/62 mmHg, a respiratory rate of 20 breaths per minute, and
an oxygen saturation of 99% on room air. Her physical exam was
unchanged from the previous day with the exception that she could
not cooperate for the neurologic exam. Her pupils were equal and
reactive to light. She did grimace in reaction to painful stimuli.
Her muscle tone was noted to be normal with no rigidity. She was
spontaneously moving all four extremities, but not on command.
The patient was transferred to the telemetry floor and a full
neurologic evaluation was initiated. A lumbar puncture was
planned, cultures were obtained, and a head CT was unremarkable,
showing no intracranial hemorrhage, acute territorial infarct, or
cerebral edema. Additionally, no mass effect or midline shift was
seen on the CT scan. The patient’s fever increased to 103ºF, and
the infectious disease specialist saw her in consult.
The patient’s condition remained unchanged until 4:45 am the
next morning, when a nurse witnessed the patient having tonicclonic seizure activity. During the seizure the patient foamed at
the mouth and desaturated to 81% on 2L oxygen by nasal canula.
She continued to seize despite 6mg intravenous lorazepam and an
intravenous fosphenytoin load. She was intubated and transferred
to the intensive care unit on the neurology service for
management of status epilepticus. In the intensive care unit she
was given intravenous fosphenytoin and propofol. A lumbar
puncture was performed for suspected encephalitis. Cerebrospinal
fluid analysis, including evaluation for cryptococcus and herpes
simplex virus, revealed no abnormalities. An MRI of her brain
showed no acute abnormalities, and a work-up for an infectious
etiology of her illness was negative. The infectious disease
consultant suspected that the patient’s seizures were a reaction to
the moxifloxacin. It was discontinued and within twenty-four
hours her seizures stopped. An EEG was performed the day after
her seizure activity and intubation. The EEG showed diffuse 2-6
Hertz slowing secondary to sedation. No seizure or epileptiform
abnormalities were seen. Three days after her initial intubation,
she was successfully weaned from the ventilator. Her mental status
quickly returned to baseline. Treatment with azithromycin was
initiated for her respiratory infection, and at the recommendation
of the neurologists, she was maintained on anti-epileptic
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medication. Her hospital course was complicated by an upper
extremity DVT during her stay in the intensive care unit. Ten
days after her initial admission she was discharged to her home
with an outpatient enoxaparin bridge to warfarin. She was
instructed to follow-up with her primary care provider, neurology,
and infectious disease as an outpatient.

Discussion
In the absence of infectious or structural etiologies of the seizures,
they were likely referable to moxifloxacin hydrochloride administration. Moxifloxacin is a normally well-tolerated fluoroquinolone
antibiotic used to treat community-acquired pneumonia, sinusitis,
and other bacterial infections. It does not require dose-modification
for renal or hepatic impairment. Some common side-effects of
moxifloxacin include upset stomach, vomiting, diarrhea, dizziness,
and headache. The product information supplied with Avelox
(brand name for moxifloxacin) notes that seizures are a rare
complication of quinolone use, and have been reported with Avelox.
It reports to “use moxifloxacin with caution in patients with known
or suspected CNS disorders (for example, severe cerebral
arteriosclerosis, epilepsy) or in the presence of other risk factors that
may predispose to seizures or lower the seizure threshold.”1

Moxifloxacin has previously been reported in the literature as
being associated with both seizures and status epilepticus. One
case report described an elderly patient with a past history of
idiopathic seizures who developed status epilepticus four days after
initiating moxifloxacin treatment for a respiratory infection. His
seizures stopped with discontinuation of the drug, but
unfortunately he subsequently died of multiorgan failure
associated with his illness.2 Additionally, an editorial noted that
the WHO Adverse Reactions database contained 53 reports of
convulsions associated with moxifloxacin.2
This report provides further evidence that moxifloxacin should be
avoided, if possible, in patients with a history of seizure disorders.
Furthermore, moxifloxacin should be considered as the possible
cause of new onset seizures in a patient who has initiated
treatment with this drug.
■
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